Search

Zentalis Pharmaceuticals Inc

Geschlossen

4.72 -3.48

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.7

Max

4.85

Schlüsselkennzahlen

By Trading Economics

Einkommen

-136K

-35M

EPS

-0.503

Angestellte

106

EBITDA

2.2M

-35M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+53.8% upside

Dividenden

By Acuity

Nächstes Ergebnis

4. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

26M

321M

Vorheriger Eröffnungskurs

8.2

Vorheriger Schlusskurs

4.72

Zentalis Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

31. Juli 2026, 23:56 UTC

In after-market trading, Invesco Ltd shares are lower, moving from a high of 0.51% to a low of -0.81%. No specific news was identified.

31. Juli 2026, 23:56 UTC

Social Media

Equifax Inc. shares are higher in after-market trading, buoyed by CEO Mark Begor's outlook on strong cash flow and $1.6 billion returned to shareholders.

31. Juli 2026, 23:56 UTC

Dutch Bros Inc. shares are lower in after-market trading, fluctuating within a routine range since Friday's close. The price remains stable in its one-month trading range.

31. Juli 2026, 23:56 UTC

MannKind Corp shares traded lower in after-market hours, retreating from earlier gains. The stock remains near the lower end of its one-month range.

31. Juli 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Welltower and raised its price target to $275. Shares are modestly higher in after-market trading.

31. Juli 2026, 23:56 UTC

iShares 1-3 Year Treasury Bond ETF trading roughly flat in after-market hours. Global equity indices are mixed, with U.S. markets lower and others higher.

31. Juli 2026, 23:56 UTC

Indie Semiconductor Inc. shares are near unchanged in after-market trading, following a notable decline over the past month and remaining below the 20-day moving average.

31. Juli 2026, 23:56 UTC

Shares of Legend Biotech Corp. are higher in after-market trading, despite a slight decline earlier in the session and broader market weakness.

31. Juli 2026, 23:56 UTC

ETF Constituents

Vanguard Real Estate ETF trading was roughly flat after hours, with CSGP, VNO, and IIPR contributing negatively while ADC provided a modest positive impact.

31. Juli 2026, 23:56 UTC

AeroVironment Inc shares are lower in after-market hours, with no specific news identified. The stock is near the lower end of its one-month range.

31. Juli 2026, 23:56 UTC

Transocean Ltd shares are higher in after-market trading, continuing a trend of gains over the past three sessions. No specific news was identified for the move.

31. Juli 2026, 23:56 UTC

Comcast shares are higher in after-market trading, showing volatility with no specific news to explain the movement. Broader market trends include gains in the Nikkei 225.

31. Juli 2026, 23:56 UTC

Correlated Moves

Texas Instruments Inc. shows little change in after-market trading, reflecting broader weakness in the technology sector amid mixed Asian market performance.

31. Juli 2026, 23:56 UTC

Barnes Group Inc. shares declined in after-market trading, showing minor fluctuations without specific news. Asian market results provided broader context for the movement.

31. Juli 2026, 23:56 UTC

Diamondback Energy Inc shares are higher in after-market trading, continuing recent upward momentum and reflecting strong investor interest amid no specific news.

31. Juli 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

31. Juli 2026, 23:56 UTC

Marathon Digital Holdings shares are higher in after-market trading, reflecting routine activity with no specific news identified. The stock remains below its 20-day moving average.

31. Juli 2026, 23:56 UTC

MSCI Inc. shares advanced in after-market trading, supported by a rise in the Nikkei 225 Index and renewed interest in AI stocks.

31. Juli 2026, 23:56 UTC

Block Inc shares are higher in after-market trading, buoyed by strong earnings from U.S. tech companies that eased concerns about AI infrastructure spending.

31. Juli 2026, 23:56 UTC

Correlated Moves

Procter & Gamble Co shares declined in after-market trading, reflecting broader sector trends as Kimberly-Clark Corp also reported a drop.

31. Juli 2026, 23:56 UTC

Adobe Inc shares are lower in after-market hours, with no specific news identified. The stock has declined since Friday's close, amid mixed broader market trends.

31. Juli 2026, 23:52 UTC

Mexican Inflation Rate Set for Release Amid Mixed Market Sentiment and Global Price Pressures

31. Juli 2026, 23:52 UTC

Mexico's Inflation Rate Release on August 7, 2026, Amidst Global Economic Pressures and Mixed Market Sentiment.

31. Juli 2026, 23:52 UTC

South Korea's July Exports Expected to Grow 0.59% YoY Amid Cautious Optimism Following Record Highs

31. Juli 2026, 23:52 UTC

Rising MBA 30-Year Mortgage Rates Reach Highest Levels Since Last Year, Signaling Caution Among Homebuyers Amid Economic Pressures.

31. Juli 2026, 23:51 UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

31. Juli 2026, 23:51 UTC

Social Media
Correlated Moves
News

Meta Platforms Inc shares are lower in after-market hours, pressured by broader market weakness and concerns over rising AI spending following a disappointing earnings report.

31. Juli 2026, 23:51 UTC

Interactive Brokers Group Inc is lower in after-market trading, reflecting the broader market's significant decline and a position below its 20-day moving average.

31. Juli 2026, 23:51 UTC

Solaredge Technologies Inc shares declined in after-hours trading, reflecting broader market trends. No specific company news was identified to explain the movement.

31. Juli 2026, 23:51 UTC

Evolent Health Inc shares are higher in after-market hours, rebounding from nine consecutive daily declines despite remaining below their 20-day moving average.

Peer-Vergleich

Kursveränderung

Zentalis Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

53.8% Vorteil

12-Monats-Prognose

Durchschnitt 7.29 USD  53.8%

Hoch 11 USD

Tief 4 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zentalis Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

8 ratings

5

Buy

3

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat